US Flag logoAn official website of the United States government
HIV+ Tumor Molecular Characterization Project
CGCI
Data Resource:  CGCI
Point of Contact:  
Center for Cancer Genomics,  
Project

About This Dataset
The Center for Cancer Genomics, along with the Office of HIV and AIDS Malignancies, initiated the HIV+ Tumor Molecular Characterization Project (HTMCP) to gain insight into the genetic events driving HIV-associated cancers and to determine why certain cancers, but not others, have higher incidences in HIV-positive patients. The molecular characterization data from patients identified through HTMCP will be available to the research community worldwide in a publicly available, yet patient privacy-protected database. Acquired immunodeficiency syndrome (AIDS) is a complex and devastating disease caused by infection with human immunodeficiency virus (HIV). The advent of highly active antiretroviral therapy has considerably slowed disease progression from HIV to full-blown AIDS, thereby increasing the number of people living with HIV. Despite this success in survivorship, certain types of cancers are becoming more prevalent in the expanding pool of HIV-infected individuals. While coinfecting viruses and, possibly, immunodeficiency may play a role in the pathogenesis of HIV-associated cancers, our understanding of its etiology is inadequate. Understanding the molecular causes of these tumors may translate into improved therapies for a growing population of patients doubly afflicted with HIV and cancer.
Core Data Elements
Number of Cases
36
Case Sex
Female (25); Male (11)
Case Age At Diagnosis
0 to 4 years (1); 5 to 9 years (1); 10 to 14 years (2); 15 to 19 years (1); 25 to 29 years (6); 30 to 34 years (12); 35 to 39 years (13)
Case Race
Black or African American (33); White (3)
Case Ethnicity
Not Hispanic or Latino (24); Not Reported (5); Unknown (7)
Case Disease Diagnosis
Adenocarcinoma, NOS (2); Diffuse Large B-cell Lymphoma, NOS (12); Kaposi Sarcoma (1); Lymphoepithelial Carcinoma (1); Squamous Cell Carcinoma, Keratinizing, NOS (5); Squamous Cell Carcinoma, Nonkeratinizing, NOS (14); Not Reported (1)
Case Tumor Site
Cervix Uteri (22); Hematopoietic system, NOS (13); Not Reported (1)
Number of Samples
72
Sample Assay Method
Methylation Array (16); miRNA Sequencing (28); RNA Sequencing (27); Targeted Sequencing (6); Tissue Slide (30); Whole Genome Sequencing (30)
Sample Analyte Type
DNA (75); RNA (32)
Sample Is Normal
Yes (36); No (36)
Additional Data Elements
DBGAP STUDY IDENTIFIER
DATA REPOSITORY
Published In
https://doi.org/10.1038/s41588-020-0673-7
Charts
Female (25); Male (11)
25Female